Publication Information

{'id': 'https://openalex.org/W2411542114', 'doi': None, 'title': '[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].', 'display_name': '[Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].', 'publication_year': 2004, 'publication_date': '2004-02-01', 'ids': {'openalex': 'https://openalex.org/W2411542114', 'mag': '2411542114', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/15045823'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://europepmc.org/article/MED/15045823', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['pubmed'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5013992115', 'display_name': 'Masaaki Takatoku', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Masaaki Takatoku', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5028581103', 'display_name': 'Kaoru Noborio-Hatano', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Kaoru Noborio-Hatano', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5003421906', 'display_name': 'Satoko Takahashi', 'orcid': 'https://orcid.org/0000-0002-7287-4343'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Satoko Takahashi', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5111371286', 'display_name': 'Satoru Kikuchi', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Satoru Kikuchi', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5067647817', 'display_name': 'Masaki Mori', 'orcid': 'https://orcid.org/0000-0001-7632-3875'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Masaki Mori', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5113555286', 'display_name': 'Kazuo Muroi', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Kazuo Muroi', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5031116384', 'display_name': 'Norio Komatsu', 'orcid': 'https://orcid.org/0000-0003-1880-9126'}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Norio Komatsu', 'raw_affiliation_strings': [], 'affiliations': []}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5108098062', 'display_name': 'Keiya Ozawa', 'orcid': None}, 'institutions': [], 'countries': [], 'is_corresponding': False, 'raw_author_name': 'Keiya Ozawa', 'raw_affiliation_strings': [], 'affiliations': []}], 'institution_assertions': [], 'countries_distinct_count': 0, 'institutions_distinct_count': 0, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 1, 'citation_normalized_percentile': {'value': 0.369674, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 61, 'max': 68}, 'biblio': {'volume': '45', 'issue': '2', 'first_page': '144', 'last_page': '148'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10649', 'display_name': 'Multiple Myeloma Research and Treatments', 'score': 0.9994, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10649', 'display_name': 'Multiple Myeloma Research and Treatments', 'score': 0.9994, 'subfield': {'id': 'https://openalex.org/subfields/2720', 'display_name': 'Hematology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11157', 'display_name': 'Chronic Lymphocytic Leukemia Research', 'score': 0.9937, 'subfield': {'id': 'https://openalex.org/subfields/2716', 'display_name': 'Genetics'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11041', 'display_name': 'Ubiquitin and proteasome pathways', 'score': 0.9864, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/refractory', 'display_name': 'Refractory (planetary science)', 'score': 0.6054387}], 'concepts': [{'id': 'https://openalex.org/C2777478702', 'wikidata': 'https://www.wikidata.org/wiki/Q419319', 'display_name': 'Bortezomib', 'level': 3, 'score': 0.95934033}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.9377172}, {'id': 'https://openalex.org/C2779609412', 'wikidata': 'https://www.wikidata.org/wiki/Q203174', 'display_name': 'Thalidomide', 'level': 3, 'score': 0.89854825}, {'id': 'https://openalex.org/C2776364478', 'wikidata': 'https://www.wikidata.org/wiki/Q467635', 'display_name': 'Multiple myeloma', 'level': 2, 'score': 0.89340043}, {'id': 'https://openalex.org/C2778367456', 'wikidata': 'https://www.wikidata.org/wiki/Q7251235', 'display_name': 'Proteasome inhibitor', 'level': 3, 'score': 0.7855617}, {'id': 'https://openalex.org/C2780401358', 'wikidata': 'https://www.wikidata.org/wiki/Q422252', 'display_name': 'Dexamethasone', 'level': 2, 'score': 0.6220316}, {'id': 'https://openalex.org/C142424586', 'wikidata': 'https://www.wikidata.org/wiki/Q7307572', 'display_name': 'Refractory (planetary science)', 'level': 2, 'score': 0.6054387}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.49913096}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.4389031}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.4271482}, {'id': 'https://openalex.org/C90924648', 'wikidata': 'https://www.wikidata.org/wiki/Q120569', 'display_name': 'Gastroenterology', 'level': 1, 'score': 0.41849336}, {'id': 'https://openalex.org/C2911091166', 'wikidata': 'https://www.wikidata.org/wiki/Q106419912', 'display_name': 'Transplantation', 'level': 2, 'score': 0.41101113}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.39460507}, {'id': 'https://openalex.org/C121332964', 'wikidata': 'https://www.wikidata.org/wiki/Q413', 'display_name': 'Physics', 'level': 0, 'score': 0.0}, {'id': 'https://openalex.org/C87355193', 'wikidata': 'https://www.wikidata.org/wiki/Q411', 'display_name': 'Astrobiology', 'level': 1, 'score': 0.0}], 'mesh': [{'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D001897', 'descriptor_name': 'Boronic Acids', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D009101', 'descriptor_name': 'Multiple Myeloma', 'qualifier_ui': 'Q000188', 'qualifier_name': 'drug therapy', 'is_major_topic': True}, {'descriptor_ui': 'D011480', 'descriptor_name': 'Protease Inhibitors', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D011719', 'descriptor_name': 'Pyrazines', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': True}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D000970', 'descriptor_name': 'Antineoplastic Agents', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D001897', 'descriptor_name': 'Boronic Acids', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D001897', 'descriptor_name': 'Boronic Acids', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D000069286', 'descriptor_name': 'Bortezomib', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D019008', 'descriptor_name': 'Drug Resistance, Neoplasm', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D006801', 'descriptor_name': 'Humans', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008297', 'descriptor_name': 'Male', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D008875', 'descriptor_name': 'Middle Aged', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D009101', 'descriptor_name': 'Multiple Myeloma', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011480', 'descriptor_name': 'Protease Inhibitors', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011480', 'descriptor_name': 'Protease Inhibitors', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D011719', 'descriptor_name': 'Pyrazines', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D011719', 'descriptor_name': 'Pyrazines', 'qualifier_ui': 'Q000008', 'qualifier_name': 'administration & dosage', 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': '', 'qualifier_name': None, 'is_major_topic': False}, {'descriptor_ui': 'D013792', 'descriptor_name': 'Thalidomide', 'qualifier_ui': 'Q000627', 'qualifier_name': 'therapeutic use', 'is_major_topic': False}], 'locations_count': 2, 'locations': [{'is_oa': False, 'landing_page_url': 'https://europepmc.org/article/MED/15045823', 'pdf_url': None, 'source': None, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, {'is_oa': False, 'landing_page_url': 'https://pubmed.ncbi.nlm.nih.gov/15045823', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S4306525036', 'display_name': 'PubMed', 'issn_l': None, 'issn': None, 'is_oa': False, 'is_in_doaj': False, 'is_core': False, 'host_organization': 'https://openalex.org/I1299303238', 'host_organization_name': 'National Institutes of Health', 'host_organization_lineage': ['https://openalex.org/I1299303238'], 'host_organization_lineage_names': ['National Institutes of Health'], 'type': 'repository'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.8, 'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3203462410', 'https://openalex.org/W3004333995', 'https://openalex.org/W2593976954', 'https://openalex.org/W2504195627', 'https://openalex.org/W2398322618', 'https://openalex.org/W2393087217', 'https://openalex.org/W2346584294', 'https://openalex.org/W2328583588', 'https://openalex.org/W2304017568', 'https://openalex.org/W2151840358', 'https://openalex.org/W2124996642', 'https://openalex.org/W2124042268', 'https://openalex.org/W2079167171', 'https://openalex.org/W2074205062', 'https://openalex.org/W2029788312', 'https://openalex.org/W2026794782', 'https://openalex.org/W2017303578', 'https://openalex.org/W2014140553', 'https://openalex.org/W2010722373', 'https://openalex.org/W1980168719'], 'abstract_inverted_index': {'A': [0], 'proteasome': [1], 'inhibitor': [2], 'with': [3, 38, 100], 'a': [4, 33, 125, 196], 'new': [5], 'molecular': [6], 'target': [7], '(PS-341:': [8], 'bortezomib)': [9], 'was': [10, 49, 78, 85, 104, 113, 130, 160], 'recently': [11], 'developed,': [12], 'and': [13, 56, 63, 74, 80, 121, 123, 146, 151], 'its': [14], 'efficacy': [15], 'in': [16, 26, 175, 182], 'the': [17, 27, 47, 67, 89, 101, 137, 139, 156, 167, 171, 176], 'treatment': [18, 177], 'of': [19, 111, 136, 155, 170, 173, 178, 186], 'refractory': [20, 39, 179], 'multiple': [21, 40, 53, 90, 180], 'myeloma': [22, 41, 54, 91, 181], 'has': [23], 'been': [24], 'reported': [25], 'United': [28], 'States.': [29], 'Here,': [30], 'we': [31], 'present': [32], '54-year-old': [34], 'Japanese': [35], 'male': [36], 'patient': [37, 48, 188], 'resistant': [42], 'to': [43], 'thalidomide.': [44], 'In': [45, 70], '1998,': [46], 'diagnosed': [50], 'as': [51], 'having': [52], '(IgG-kappa)': [55], 'underwent': [57], 'chemotherapy,': [58], 'autologous': [59], 'hematopoietic': [60], 'cell': [61], 'transplantation': [62], 'interferon': [64], 'therapy,': [65], 'but': [66], 'disease': [68], 'recurred.': [69], 'December': [71], '2002,': [72], 'thalidomide': [73], 'high-dose': [75], 'dexamethasone': [76], 'therapy': [77, 84, 99, 197], 'initiated,': [79], 'while': [81], 'this': [82, 165, 187, 199], 'combination': [83], 'effective': [86], 'at': [87], 'first,': [88], 'became': [92], 'unresponsive.': [93], 'On': [94], '23': [95], 'June': [96], '2003,': [97], 'bortezomib': [98, 112, 174], 'following': [102], 'regime': [103], 'therefore': [105], 'started:': [106], '2.2': [107], 'mg': [108], '(1.3': [109], 'mg/m2)': [110], 'injected': [114], 'intravenously': [115], 'on': [116, 133], 'days': [117], '1,': [118], '4,': [119], '8': [120, 135], '11,': [122], 'after': [124, 152], 'one-week': [126], 'break,': [127], 'another': [128], 'cycle': [129], 'performed.': [131], 'Starting': [132], 'day': [134, 153], 'administration,': [138, 157], 'serum': [140, 144], 'total': [141], 'protein,': [142], 'IgG,': [143], 'calcium': [145], 'LDH': [147], 'levels': [148], 'decreased': [149], 'rapidly,': [150], '45': [154], 'blood': [158], 'transfusion': [159], 'no': [161], 'longer': [162], 'needed.': [163], 'Since': [164], 'is': [166], 'first': [168], 'report': [169], 'use': [172], 'Japan,': [183], 'further': [184], 'monitoring': [185], 'will': [189], 'provide': [190], 'extremely': [191], 'valuable': [192], 'information': [193], 'for': [194], 'developing': [195], 'against': [198], 'disease.': [200]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2411542114', 'counts_by_year': [], 'updated_date': '2024-12-08T11:00:42.225078', 'created_date': '2016-06-24'}